Last reviewed · How we verify
Prophylactic Vancomycin
Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.
Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption. Used for Prophylaxis of bacterial infections in immunocompromised cancer patients undergoing chemotherapy.
At a glance
| Generic name | Prophylactic Vancomycin |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Drug class | Glycopeptide antibiotic |
| Target | Bacterial peptidoglycan D-Ala-D-Ala precursors |
| Modality | Small molecule |
| Therapeutic area | Oncology / Infectious Disease Prevention |
| Phase | Phase 3 |
Mechanism of action
Vancomycin binds to the terminal D-alanyl-D-alanine residues of peptidoglycan precursors in bacterial cell walls, blocking the cross-linking reactions catalyzed by transpeptidases. This prevents proper cell wall formation and integrity, leading to bacterial cell lysis and death. In prophylactic use, vancomycin is administered to prevent bacterial infections in immunocompromised cancer patients at high risk of infection.
Approved indications
- Prophylaxis of bacterial infections in immunocompromised cancer patients undergoing chemotherapy
Common side effects
- Nephrotoxicity
- Ototoxicity
- Red man syndrome (flushing, erythema)
- Phlebitis at infusion site
- Hypersensitivity reactions
Key clinical trials
- Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial (PHASE4)
- Local Antibiotics for Breast Implants (PHASE3)
- Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial (PHASE4)
- Intraosseous vs. Intravenous Vancomycin Prophylaxis for Diabetic Foot Amputations: A Randomized Trial (PHASE4)
- FMT for Lung and Associated-organ Rescue Efficacy in Pulmonary Infection With MDROs (NA)
- Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT (PHASE3)
- Using Antibiotics to Prevent Infections in Hemodialysis Patients During Catheter Placement (PHASE4)
- Vancomycin and Tobramycin Powder Use in Acute Open Fractures (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prophylactic Vancomycin CI brief — competitive landscape report
- Prophylactic Vancomycin updates RSS · CI watch RSS
- Memorial Sloan Kettering Cancer Center portfolio CI